Additional Paid in Capital of CITIUS ONCOLOGY, INC. from 31 Dec 2021 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
- Summary
-
CITIUS ONCOLOGY, INC. quarterly Additional Paid in Capital in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
- CITIUS ONCOLOGY, INC. Additional Paid in Capital for the quarter ending 31 Dec 2025 was $127,979,246, a 47% increase year-over-year.
- Source SEC data
- View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)
CITIUS ONCOLOGY, INC. Quarterly Additional Paid in Capital (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $127,979,246 | +$40,758,997 | +47% | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q3 2025 | $108,897,836 | +$23,486,065 | +27% | 30 Sep 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q2 2025 | $91,434,058 | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q3 | ||
| Q1 2025 | $89,308,821 | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q2 | ||
| Q4 2024 | $87,220,249 | 31 Dec 2024 | 10-Q | 14 Feb 2025 | 2025 | Q1 | ||
| Q3 2024 | $85,411,771 | +$41,753,021 | +96% | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| Q3 2023 | $43,658,750 | +$43,633,923 | 30 Sep 2023 | 10-K | 27 Dec 2024 | 2024 | FY | |
| Q3 2022 | $24,827* | 30 Sep 2022 | 10-Q | 28 Nov 2022 | 2022 | Q3 | ||
| Q4 2021 | $24,827* | 31 Dec 2021 | 10-K | 17 Apr 2023 | 2022 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.